检索规则说明:AND代表“并且”;OR代表“或者”;NOT代表“不包含”;(注意必须大写,运算符两边需空一格)
检 索 范 例 :范例一: (K=图书馆学 OR K=情报学) AND A=范并思 范例二:J=计算机应用与软件 AND (U=C++ OR U=Basic) NOT M=Visual
作 者:杨琪 臧彦楠 庄红艳[1,2] 果伟 YANG Qi;ZANG Yan-nan;ZHUANG Hong-yan;GUO Wei(The National Clinical Research Center for Mental Disorders&Beijing Key Laboratory of Mental Disorders,Beijing Anding Hospital,Capital Medical University,Beijing 100088,China;Advanced Innovation Center for Human Brain Protection,Capital Medical University,Beijing 100069,China)
机构地区:[1]首都医科大学附属北京安定医院药事部,国家精神心理疾病临床医学研究中心,精神疾病诊断与治疗北京市重点实验室,北京100088 [2]人脑保护高精尖创新中心,首都医科大学,北京100069
出 处:《中国医院药学杂志》2020年第13期1479-1483,共5页Chinese Journal of Hospital Pharmacy
基 金:首都卫生发展科研专项(编号:2018-4-2124);北京市属医院科研培育计划(编号:PX2019069)。
摘 要:目的:分析"4+7"带量采购对SSRI类抗抑郁药使用的影响,为政策制定和医院药事管理提供参考。方法:采用药物经济学方法对"4+7"实施后6个月和2018年同期6个月门诊SSRI类抗抑郁药的数量、金额、用药频度(DDDs)、日均费用(DDC)等进行分析。结果:"4+7"后,艾司西酞普兰片数显著增长,帕罗西汀金额明显下降。艾司西酞普兰的DDDs值增幅较大。艾司西酞普兰和帕罗西汀的DDC值较去年同期都下降明显。结论:本次"4+7"政策落地半年,切实降低了部分患者的用药负担,提升了医保基金的使用效率。OBJECTIVE To analyze the influence of the pharmaceutical procurement with target quantity("4+7")of selective serotonin reuptake inhibitors(SSRIs), and to provide reference for policy formulation and hospital drug management.METHODS The method of pharmacoeconomics was used to analyze sales amount, sales volume, defined daily doses(DDDs), defined daily cost(DDC) of 6 months after implementation of "4+7" and corresponding period of 2018.RESULTS After the implementation of "4+7", the usage volume of escitalopram was substantially increased, and the sales amount of paroxetine was sharply decreased. The DDDs of escitalopram were increased significantly, while the DDC of escitalopram and paroxetine were decreased significantly.CONCLUSION The implementation of the "4+7" policy for half a year has effectively reduced the medication burden of some patients and improved the use efficiency of medical insurance fund.
关 键 词:带量采购 选择性5-羟色胺再摄取抑制剂类(SSRIs) 用药频度 日用药金额
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在链接到云南高校图书馆文献保障联盟下载...
云南高校图书馆联盟文献共享服务平台 版权所有©
您的IP:216.73.216.49